Development of the DAS

Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, Limburg PC.

J Rheumatol. 1994 Mar;21(3):425-9.

 

Development of a disease activity score based on judgment in clinical practice by rheumatologists.

van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB.

J Rheumatol. 1993 Mar;20(3):579-81.

 

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

van Gestel AM, Haagsma CJ, van Riel PL.

Arthritis Rheum. 1998 Oct;41(10):1845-50. doi: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K.

 

Validity of single variables and indices to measure disease activity in rheumatoid arthritis.

van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB.

J Rheumatol. 1993 Mar;20(3):538-41.

 

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB.

Ann Rheum Dis. 1990 Nov;49(11):916-20. doi: 10.1136/ard.49.11.916.

 

Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis.

Prevoo ML, van Riel PL, van 't Hof MA, van Rijswijk MH, van Leeuwen MA, Kuper HH, van de Putte LB.

Br J Rheumatol. 1993 Jul;32(7):589-94. doi: 10.1093/rheumatology/32.7.589.

 

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB.

Ann Rheum Dis. 1992 Feb;51(2):177-81. doi: 10.1136/ard.51.2.177.

 

Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability.

Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, Lolkema WF, van Rijswijk MH.

Br J Rheumatol. 1997 Aug;36(8):855-60. doi: 10.1093/rheumatology/36.8.855.

 

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, Smolen JS, Khaltaev N, Muirden KD.

J Rheumatol Suppl. 1994 Sep;41:86-9.

 

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.

Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL.

Ann Rheum Dis. 2009 Jun;68(6):954-60. doi: 10.1136/ard.2007.084459. Epub 2008 May 19.

 

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.

Arthritis Rheum. 1995 Jan;38(1):44-8. doi: 10.1002/art.1780380107.

 

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.

Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL.

Arthritis Rheum. 2001 Sep;44(9):2009-17. doi: 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L.

 

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.

Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM.

Arthritis Rheum. 2004 Jul;50(7):2082-93. doi: 10.1002/art.20350.

 

Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis.

Radovits BJ, Fransen J, van Riel PL, Laan RF.

Ann Rheum Dis. 2008 Aug;67(8):1127-31. doi: 10.1136/ard.2007.079913. Epub 2007 Oct 27.

 

Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Siemons L, Vonkeman HE, ten Klooster PM, van Riel PL, van de Laar MA.

Clin Rheumatol. 2014 Jun;33(6):783-9. doi: 10.1007/s10067-014-2538-x. Epub 2014 Feb 23.

 

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.

Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS, Aletaha D, van Riel P, Wells G.

Ann Rheum Dis. 2009 Apr;68(4):484-9. doi: 10.1136/ard.2008.092577. Epub 2008 Dec 11.

 

TIGHT CONTROL

 

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.

Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, van Riel P, Fransen J, van de Laar MA.

Ann Rheum Dis. 2012 Jun;71(6):845-50. doi: 10.1136/annrheumdis-2011-200274. Epub 2011 Dec 30.

 

Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome.

Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J.

Rheumatology (Oxford). 2010 Nov;49(11):2154-64. doi: 10.1093/rheumatology/keq195. Epub 2010 Jul 29.

 

Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.

Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, van de Laar MA.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1219-26. doi: 10.1002/acr.21984.

 

Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.

Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.

Arthritis Rheum. 2011 Oct;63(10):2865-72. doi: 10.1002/art.30494.

 

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.

Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, den Broeder AA, van Riel PL, Fransen J, van de Laar MA.

BMC Musculoskelet Disord. 2013 Dec 13;14:350. doi: 10.1186/1471-2474-14-350.

 

Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.

Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, van de Laar MA.

Arthritis Res Ther. 2012 Nov 23;14(6):R254. doi: 10.1186/ar4099.

 

RESPONSE CRITERIA

 

Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers.

van Riel PL, van Gestel AM, van de Putte LB.

Br J Rheumatol. 1996 Sep;35 Suppl 2:4-7. doi: 10.1093/rheumatology/35.suppl_2.4.

 

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL.

Arthritis Rheum. 1996 Jan;39(1):34-40. doi: 10.1002/art.1780390105.

 

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score.

Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL.

Br J Rheumatol. 1996 Nov;35(11):1101-5. doi: 10.1093/rheumatology/35.11.1101.

 

Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis?

van Riel PL, van Gestel AM.

Arthritis Rheum. 2001 Jul;44(7):1719-21. doi: 10.1002/1529-0131(200107)44:7<1719::AID-ART300>3.0.CO;2-2.

 

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

Fransen J, Creemers MC, Van Riel PL.

Rheumatology (Oxford). 2004 Oct;43(10):1252-5. doi: 10.1093/rheumatology/keh297. Epub 2004 Jul 6.

 

Time to achieve remission determines time to be in remission.

Schipper LG, Fransen J, den Broeder AA, Van Riel PL.

Arthritis Res Ther. 2010;12(3):R97. doi: 10.1186/ar3027. Epub 2010 May 20.

 

The Disease Activity Score and the EULAR response criteria.

Fransen J, van Riel PL.

Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9.

 

DAILY CLINICAL PRACTICE

 

Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha.

Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL.

Rheumatology (Oxford). 2002 Jun;41(6):638-42. doi: 10.1093/rheumatology/41.6.638.

 

Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade.

Spijk-de Jonge MJ, Weijers JM, Boerboom LWM, Huis AMP, Atsma F, Van Hulst LTC, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM.

Clin Rheumatol. 2020 Apr;39(4):1131-1139. doi: 10.1007/s10067-019-04913-7. Epub 2020 Jan 29.

 

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study.

van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, Woodworth T, den Broeder AA.

Ann Rheum Dis. 2013 Nov;72(11):1800-5. doi: 10.1136/annrheumdis-2012-202281. Epub 2012 Nov 23.

 

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis.

van Riel PL, Fransen J.

Arthritis Res Ther. 2005;7(5):189-90. doi: 10.1186/ar1820. Epub 2005 Aug 22.

 

Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.

Flendrie M, Creemers MC, van Riel PL.

Rheumatology (Oxford). 2007 Jan;46(1):146-9. doi: 10.1093/rheumatology/kel173. Epub 2006 Jun 16.

 

Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis.

Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, Fransen J.

Ann Rheum Dis. 2009 Aug;68(8):1271-6. doi: 10.1136/ard.2008.089862. Epub 2008 Aug 13.

 

Guidelines

 

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.


2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.

England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O'Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K.

Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555. doi: 10.1002/acr.24042. Epub 2019 Nov 11.

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D.

Ann Rheum Dis. 2008 Oct;67(10):1360-4. doi: 10.1136/ard.2008.091454.

Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012 Jun;51(6):1076-80. doi: 10.1093/rheumatology/ker425. Epub 2012 Feb 1.

 

Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.

Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, Emery P, Felson D, Gomez-Reino J, Keystone E, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Richards P, van Riel P, Siegel J, Smolen JS, Sokka T, van der Heijde D, van Vollenhoven R, Ward M, Wells G, Zink A, Landewe R.

Ann Rheum Dis. 2008 Oct;67(10):1365-73. doi: 10.1136/ard.2008.092353.

 

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D; EULAR; ACR.

Arthritis Rheum. 2008 Oct 15;59(10):1371-7. doi: 10.1002/art.24123.

 

Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis.

Fransen J, Laan RF, Van Der Laar MA, Huizinga TW, Van Riel PL.

Ann Rheum Dis. 2004 Oct;63(10):1222-6. doi: 10.1136/ard.2003.018861.

 

PROMS and self administered joint counts

 

Validity and reproducibility of self-administered joint counts. A prospective longitudinal followup study in patients with rheumatoid arthritis.

Prevoo ML, Kuper IH, van't Hof MA, van Leeuwen MA, van de Putte LB, van Riel PL.

J Rheumatol. 1996 May;23(5):841-5.

 

Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health.

Kievit W, Welsing PM, Adang EM, Eijsbouts AM, Krabbe PF, van Riel PL.

Arthritis Rheum. 2006 Oct 15;55(5):745-50. doi: 10.1002/art.22225.

 

Patients' experiences regarding self-monitoring of the disease course: an observational pilot study in patients with inflammatory rheumatic diseases at a rheumatology outpatient clinic in The Netherlands.

Renskers L, Rongen-van Dartel SA, Huis AM, van Riel PL.

BMJ Open. 2020 Aug 20;10(8):e033321. doi: 10.1136/bmjopen-2019-033321.

 

The relationship between change in subjective outcome and change in disease: a potential paradox.

Kievit W, Hendrikx J, Stalmeier PF, van de Laar MA, Van Riel PL, Adang EM.

Qual Life Res. 2010 Sep;19(7):985-94. doi: 10.1007/s11136-010-9665-x. Epub 2010 May 8.

 

Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis.

Kievit W, van Hulst L, van Riel P, Fraenkel L.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):842-7. doi: 10.1002/acr.20123.